Proteostasis Therapeutics has named Mark J. Enyedy chief executive officer. Enyedy joins Proteostasis after serving 15 years at Genzyme, most recently as president of the transplant, oncology and multiple sclerosis divisions. Enyedy has also been elected to the Proteostasis board of directors.
“Mark’s background in building businesses in multiple therapeutic areas at a large, yet entrepreneurial company will be invaluable to Proteostasis,” said Chris Mirabelli, chairman of the Proteostasis board of directors. “His experience in operations, R&D management and business development is an ideal fit for a company of our stage.”